Cellular Dynamics International (CDI) has signed a long-term agreement with the Nestlé Institute of Health Sciences (NIHS) to supply the nutrition-focused institute with iCell® and MyCell® products.
NIHS is planning to use CDI's cell lines to develop cell models based on adult-derived induced pluripotent stem cells (iPSCs) that it hopes will help illuminate molecular contributors to diseases such as diabetes and obesity. The institute says the cell products will aid in several areas it is currently investigating including gastrointestinal health, metabolic health, and brain health.
CDI's iCell product line, the firm says, includes cardiomyocytes, neurons, hepatocytes, and endothelial cells, and its MyCell products enable the manufacture of iPSCs and terminally differentiated cells from donor samples, including donors with diseases of interest.
"Our customers already benefit from a reliable supply of human iPSCs and human differentiated cells for their biomedical research and drug discovery," CDI's CEO Bob Palay said in a statement. "This supply agreement with NIHS adds nutritional research as yet another field that will benefit from CDI's products and expertise."